|
|
 Previous Article | Table of Contents | Next Article 
Leukemias with megakaryoblastic involvement: clinical, hematologic, and
immunologic characteristics
JF San Miguel, M Gonzalez, MC Canizo, E Ojeda, A Orfao, MD Caballero, MJ Moro, P Fisac and A Lopez Borrasca
Servicio de Hematologia, Hospital Clinico Universitario, Salamanca, Spain.
The clinical, hematologic, and phenotypic features of 28 patients with
acute leukemia with megakaryocytic involvement (AMKL) were analyzed. The
prevalence of this type of leukemia in the entire series was 11.6%, with a
higher incidence among patients with acute transformation of a previous
myeloproliferative disorder (MPD) (24%) than among the transformed
myelodysplastic syndrome (13%) patients. The incidence in the "de novo"
ANLL was 8% and 16% among secondary leukemias. The presence of bone marrow
fibrosis together with low WBC and normal or increased platelet counts
despite a severe anemia are the most relevant features in these patients
who otherwise displayed an apparently poor prognosis. Megakaryoblasts were
morphologically recognized more frequently in the acute transformations of
MPD than in de novo ANLL. Only two cases were considered pure AMKL, and in
the remaining 26 patients, megakaryoblasts coexisted with other
granulomonocytic and/or erythroid populations. Antiglycoprotein IIIa
(anti-GPIIIa) (C17) and anti-GPIIb/IIIa (CDw41-, J15-) antibodies are
probably the best markers for AMKL, although the monoclonal antibody
against GPIX (FMC25) was also positive in a majority of cases but in a
lower percentage of cells. On the other hand, megakaryoblasts were
generally negative for granulocytic or monocytic markers (CD13, CD14,
CD15); the expression of HLA-DR antigens in these cells was variable. Our
present results indicate that megakaryoblastic involvement is more common
than previously recognized. This is true not only in acute transformed
leukemias but also in de novo ANLL. Although the diagnosis of these cases
should be based on megakaryocytic markers, it is often possible to suspect
a diagnosis according to certain clinical and hematologic features.
Volume 72,
Issue 2,
pp. 402-407,
08/01/1988
Copyright © 1988 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
U. H. Athale, B. I. Razzouk, S. C. Raimondi, X. Tong, F. G. Behm, D. R. Head, D. K. Srivastava, J. E. Rubnitz, L. Bowman, C.-H. Pui, et al.
Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience
Blood,
June 15, 2001;
97(12):
3727 - 3732.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Tallman, D. Neuberg, J. M. Bennett, C. J. Francois, E. Paietta, P. H. Wiernik, G. Dewald, P. A. Cassileth, M. M. Oken, and J. M. Rowe
Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience
Blood,
October 1, 2000;
96(7):
2405 - 2411.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Orfao, G. Schmitz, B. Brando, A. Ruiz-Arguelles, G. Basso, R. Braylan, G. Rothe, F. Lacombe, F. Lanza, S. Papa, et al.
Clinically Useful Information Provided by the Flow Cytometric Immunophenotyping of Hematological Malignancies: Current Status and Future Directions
Clin. Chem.,
October 1, 1999;
45(10):
1708 - 1717.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
